Q2 2026
Released Nov 10, 2025, before the open
10-Q filed Nov 10, 2025, 41 days after period end · 0001764013-25-000149
Q2 2026 · 10-Q
Revenue—
Net Income-$126.50M-$126.50M N/M vs Q2 2025N/M vs Q1 2026
EPS Diluted-$0.73-$0.73 N/M vs Q2 2025N/M vs Q1 2026
Operating Cash Flowderived-$102,515,000N/M
Free Cash Flowderived-$102,515,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$126.50M | -$109.12M | -$58.66M | -$47.93M |
| EPS Diluted | -$0.73 | -$0.74 | -$0.45 | -$0.41 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR